Triple-negative breast cancer therapeutic resistance: Where is the Achilles' heel?
Triple-negative breast cancer (TNBC) shows a higher response rate to systemic therapy compared with other breast cancer subtypes. However, the tumor differentiation of TNBC is poorer, with an early tendency to metastasis and a higher recurrence rate. Relapsed and metastatic TNBCs usually progress mo...
Gespeichert in:
| Veröffentlicht in: | Cancer letters 2021-01, Vol.497, p.100-111 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 111 |
|---|---|
| container_issue | |
| container_start_page | 100 |
| container_title | Cancer letters |
| container_volume | 497 |
| creator | Bai, Xupeng Ni, Jie Beretov, Julia Graham, Peter Li, Yong |
| description | Triple-negative breast cancer (TNBC) shows a higher response rate to systemic therapy compared with other breast cancer subtypes. However, the tumor differentiation of TNBC is poorer, with an early tendency to metastasis and a higher recurrence rate. Relapsed and metastatic TNBCs usually progress more rapidly, showing strong resistance to chemotherapy and radiotherapy. Due to the lack of combinatorial targeted drugs, alternative treatments fail to improve these patient's prognosis and the quality of life. Finding the Achilles' heel of TNBC is critical for patients with advanced TNBC. Here, we summarize the latest advances in the mechanisms underlying TNBC therapeutic resistance, consider how these mechanisms may affect the development and utilization of TNBC targeted drugs, and discuss the rationale of relevant signals as therapeutic targets. Also, we review the clinical trials registered in ClinicalTrial.gov for TNBC patients, which comprehensively reveals current research and development of novel TNBC targeted drugs and future trends.
•DNA repair is closely associated with TNBC therapeutic resistance.•Tumor microenvironment contributes greatly to the malignancy of TNBC.•PI3Kα-specific and ATK inhibitors demonstrate promising efficacy against TNBC.•PARP1 and AR inhibitors are effective for TNBC under the guidance of gene subtyping.•Immunotherapy is the current development trend of targeted drugs against TNBC. |
| doi_str_mv | 10.1016/j.canlet.2020.10.016 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2452100566</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0304383520305425</els_id><sourcerecordid>2465722133</sourcerecordid><originalsourceid>FETCH-LOGICAL-c390t-e31c35598b2caeb473a2b8a94c6e82570c1f79c5c25c12ea07d7d2659345a6623</originalsourceid><addsrcrecordid>eNp9kE1LwzAYgIMoOqf_QKTgQS-d-WiS1oMyhl8wEGTiMaTpO5fRrTNJB_57Uzo9ePAUeHjeN8mD0BnBI4KJuF6OjF7XEEYU0w6NItxDA5JLmsoix_togBnOUpYzfoSOvV9ijHkm-SE6YgyLQopigF5nzm5qSNfwoYPdQlI60D4kcbcBl4QFOL2BNliTOPDWh47fJO-RQ2J9JyRjs7B1Df4yWQDUdyfoYK5rD6e7c4jeHu5nk6d0-vL4PBlPU8MKHFJgxDDOi7ykRkOZSaZpmesiMwJyyiU2ZC4Lww3lhlDQWFayooIXLONaCMqG6Krfu3HNZws-qJX1Bupar6FpvaIZpyR-WYioXvxRl03r1vF10RJcUkoYi1bWW8Y13juYq42zK-2-FMGqa66Wqm-uuuYdjTCOne-Wt-UKqt-hn8hRuO0FiDW2FpzyxkLsWFkHJqiqsf_f8A1tPZKr</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2465722133</pqid></control><display><type>article</type><title>Triple-negative breast cancer therapeutic resistance: Where is the Achilles' heel?</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Bai, Xupeng ; Ni, Jie ; Beretov, Julia ; Graham, Peter ; Li, Yong</creator><creatorcontrib>Bai, Xupeng ; Ni, Jie ; Beretov, Julia ; Graham, Peter ; Li, Yong</creatorcontrib><description>Triple-negative breast cancer (TNBC) shows a higher response rate to systemic therapy compared with other breast cancer subtypes. However, the tumor differentiation of TNBC is poorer, with an early tendency to metastasis and a higher recurrence rate. Relapsed and metastatic TNBCs usually progress more rapidly, showing strong resistance to chemotherapy and radiotherapy. Due to the lack of combinatorial targeted drugs, alternative treatments fail to improve these patient's prognosis and the quality of life. Finding the Achilles' heel of TNBC is critical for patients with advanced TNBC. Here, we summarize the latest advances in the mechanisms underlying TNBC therapeutic resistance, consider how these mechanisms may affect the development and utilization of TNBC targeted drugs, and discuss the rationale of relevant signals as therapeutic targets. Also, we review the clinical trials registered in ClinicalTrial.gov for TNBC patients, which comprehensively reveals current research and development of novel TNBC targeted drugs and future trends.
•DNA repair is closely associated with TNBC therapeutic resistance.•Tumor microenvironment contributes greatly to the malignancy of TNBC.•PI3Kα-specific and ATK inhibitors demonstrate promising efficacy against TNBC.•PARP1 and AR inhibitors are effective for TNBC under the guidance of gene subtyping.•Immunotherapy is the current development trend of targeted drugs against TNBC.</description><identifier>ISSN: 0304-3835</identifier><identifier>EISSN: 1872-7980</identifier><identifier>DOI: 10.1016/j.canlet.2020.10.016</identifier><identifier>PMID: 33069769</identifier><language>eng</language><publisher>Ireland: Elsevier B.V</publisher><subject>Androgens ; Animals ; Antineoplastic Agents - therapeutic use ; Antioxidants ; Biosynthesis ; Breast cancer ; Cancer therapies ; Cell cycle ; Chemotherapy ; Clinical trial ; Clinical trials ; Cytochrome ; Deoxyribonucleic acid ; DNA ; DNA damage ; DNA methylation ; DNA repair ; Drug development ; Drug Resistance, Neoplasm ; Drugs ; Enzymes ; Female ; Growth factors ; Humans ; Immunotherapy ; Kinases ; Medical prognosis ; Metabolism ; Metastases ; Molecular Targeted Therapy ; Proteins ; Quality of life ; Radiation therapy ; Targeted drug ; Therapeutic resistance ; TNBC ; Triple Negative Breast Neoplasms - drug therapy ; Triple Negative Breast Neoplasms - metabolism ; Triple Negative Breast Neoplasms - pathology ; Tumor microenvironment</subject><ispartof>Cancer letters, 2021-01, Vol.497, p.100-111</ispartof><rights>2020 Elsevier B.V.</rights><rights>Copyright © 2020 Elsevier B.V. All rights reserved.</rights><rights>2020. Elsevier B.V.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c390t-e31c35598b2caeb473a2b8a94c6e82570c1f79c5c25c12ea07d7d2659345a6623</citedby><cites>FETCH-LOGICAL-c390t-e31c35598b2caeb473a2b8a94c6e82570c1f79c5c25c12ea07d7d2659345a6623</cites><orcidid>0000-0001-5582-0020</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.canlet.2020.10.016$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33069769$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bai, Xupeng</creatorcontrib><creatorcontrib>Ni, Jie</creatorcontrib><creatorcontrib>Beretov, Julia</creatorcontrib><creatorcontrib>Graham, Peter</creatorcontrib><creatorcontrib>Li, Yong</creatorcontrib><title>Triple-negative breast cancer therapeutic resistance: Where is the Achilles' heel?</title><title>Cancer letters</title><addtitle>Cancer Lett</addtitle><description>Triple-negative breast cancer (TNBC) shows a higher response rate to systemic therapy compared with other breast cancer subtypes. However, the tumor differentiation of TNBC is poorer, with an early tendency to metastasis and a higher recurrence rate. Relapsed and metastatic TNBCs usually progress more rapidly, showing strong resistance to chemotherapy and radiotherapy. Due to the lack of combinatorial targeted drugs, alternative treatments fail to improve these patient's prognosis and the quality of life. Finding the Achilles' heel of TNBC is critical for patients with advanced TNBC. Here, we summarize the latest advances in the mechanisms underlying TNBC therapeutic resistance, consider how these mechanisms may affect the development and utilization of TNBC targeted drugs, and discuss the rationale of relevant signals as therapeutic targets. Also, we review the clinical trials registered in ClinicalTrial.gov for TNBC patients, which comprehensively reveals current research and development of novel TNBC targeted drugs and future trends.
•DNA repair is closely associated with TNBC therapeutic resistance.•Tumor microenvironment contributes greatly to the malignancy of TNBC.•PI3Kα-specific and ATK inhibitors demonstrate promising efficacy against TNBC.•PARP1 and AR inhibitors are effective for TNBC under the guidance of gene subtyping.•Immunotherapy is the current development trend of targeted drugs against TNBC.</description><subject>Androgens</subject><subject>Animals</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Antioxidants</subject><subject>Biosynthesis</subject><subject>Breast cancer</subject><subject>Cancer therapies</subject><subject>Cell cycle</subject><subject>Chemotherapy</subject><subject>Clinical trial</subject><subject>Clinical trials</subject><subject>Cytochrome</subject><subject>Deoxyribonucleic acid</subject><subject>DNA</subject><subject>DNA damage</subject><subject>DNA methylation</subject><subject>DNA repair</subject><subject>Drug development</subject><subject>Drug Resistance, Neoplasm</subject><subject>Drugs</subject><subject>Enzymes</subject><subject>Female</subject><subject>Growth factors</subject><subject>Humans</subject><subject>Immunotherapy</subject><subject>Kinases</subject><subject>Medical prognosis</subject><subject>Metabolism</subject><subject>Metastases</subject><subject>Molecular Targeted Therapy</subject><subject>Proteins</subject><subject>Quality of life</subject><subject>Radiation therapy</subject><subject>Targeted drug</subject><subject>Therapeutic resistance</subject><subject>TNBC</subject><subject>Triple Negative Breast Neoplasms - drug therapy</subject><subject>Triple Negative Breast Neoplasms - metabolism</subject><subject>Triple Negative Breast Neoplasms - pathology</subject><subject>Tumor microenvironment</subject><issn>0304-3835</issn><issn>1872-7980</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE1LwzAYgIMoOqf_QKTgQS-d-WiS1oMyhl8wEGTiMaTpO5fRrTNJB_57Uzo9ePAUeHjeN8mD0BnBI4KJuF6OjF7XEEYU0w6NItxDA5JLmsoix_togBnOUpYzfoSOvV9ijHkm-SE6YgyLQopigF5nzm5qSNfwoYPdQlI60D4kcbcBl4QFOL2BNliTOPDWh47fJO-RQ2J9JyRjs7B1Df4yWQDUdyfoYK5rD6e7c4jeHu5nk6d0-vL4PBlPU8MKHFJgxDDOi7ykRkOZSaZpmesiMwJyyiU2ZC4Lww3lhlDQWFayooIXLONaCMqG6Krfu3HNZws-qJX1Bupar6FpvaIZpyR-WYioXvxRl03r1vF10RJcUkoYi1bWW8Y13juYq42zK-2-FMGqa66Wqm-uuuYdjTCOne-Wt-UKqt-hn8hRuO0FiDW2FpzyxkLsWFkHJqiqsf_f8A1tPZKr</recordid><startdate>20210128</startdate><enddate>20210128</enddate><creator>Bai, Xupeng</creator><creator>Ni, Jie</creator><creator>Beretov, Julia</creator><creator>Graham, Peter</creator><creator>Li, Yong</creator><general>Elsevier B.V</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TO</scope><scope>7U9</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-5582-0020</orcidid></search><sort><creationdate>20210128</creationdate><title>Triple-negative breast cancer therapeutic resistance: Where is the Achilles' heel?</title><author>Bai, Xupeng ; Ni, Jie ; Beretov, Julia ; Graham, Peter ; Li, Yong</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c390t-e31c35598b2caeb473a2b8a94c6e82570c1f79c5c25c12ea07d7d2659345a6623</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Androgens</topic><topic>Animals</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Antioxidants</topic><topic>Biosynthesis</topic><topic>Breast cancer</topic><topic>Cancer therapies</topic><topic>Cell cycle</topic><topic>Chemotherapy</topic><topic>Clinical trial</topic><topic>Clinical trials</topic><topic>Cytochrome</topic><topic>Deoxyribonucleic acid</topic><topic>DNA</topic><topic>DNA damage</topic><topic>DNA methylation</topic><topic>DNA repair</topic><topic>Drug development</topic><topic>Drug Resistance, Neoplasm</topic><topic>Drugs</topic><topic>Enzymes</topic><topic>Female</topic><topic>Growth factors</topic><topic>Humans</topic><topic>Immunotherapy</topic><topic>Kinases</topic><topic>Medical prognosis</topic><topic>Metabolism</topic><topic>Metastases</topic><topic>Molecular Targeted Therapy</topic><topic>Proteins</topic><topic>Quality of life</topic><topic>Radiation therapy</topic><topic>Targeted drug</topic><topic>Therapeutic resistance</topic><topic>TNBC</topic><topic>Triple Negative Breast Neoplasms - drug therapy</topic><topic>Triple Negative Breast Neoplasms - metabolism</topic><topic>Triple Negative Breast Neoplasms - pathology</topic><topic>Tumor microenvironment</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bai, Xupeng</creatorcontrib><creatorcontrib>Ni, Jie</creatorcontrib><creatorcontrib>Beretov, Julia</creatorcontrib><creatorcontrib>Graham, Peter</creatorcontrib><creatorcontrib>Li, Yong</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>Cancer letters</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bai, Xupeng</au><au>Ni, Jie</au><au>Beretov, Julia</au><au>Graham, Peter</au><au>Li, Yong</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Triple-negative breast cancer therapeutic resistance: Where is the Achilles' heel?</atitle><jtitle>Cancer letters</jtitle><addtitle>Cancer Lett</addtitle><date>2021-01-28</date><risdate>2021</risdate><volume>497</volume><spage>100</spage><epage>111</epage><pages>100-111</pages><issn>0304-3835</issn><eissn>1872-7980</eissn><abstract>Triple-negative breast cancer (TNBC) shows a higher response rate to systemic therapy compared with other breast cancer subtypes. However, the tumor differentiation of TNBC is poorer, with an early tendency to metastasis and a higher recurrence rate. Relapsed and metastatic TNBCs usually progress more rapidly, showing strong resistance to chemotherapy and radiotherapy. Due to the lack of combinatorial targeted drugs, alternative treatments fail to improve these patient's prognosis and the quality of life. Finding the Achilles' heel of TNBC is critical for patients with advanced TNBC. Here, we summarize the latest advances in the mechanisms underlying TNBC therapeutic resistance, consider how these mechanisms may affect the development and utilization of TNBC targeted drugs, and discuss the rationale of relevant signals as therapeutic targets. Also, we review the clinical trials registered in ClinicalTrial.gov for TNBC patients, which comprehensively reveals current research and development of novel TNBC targeted drugs and future trends.
•DNA repair is closely associated with TNBC therapeutic resistance.•Tumor microenvironment contributes greatly to the malignancy of TNBC.•PI3Kα-specific and ATK inhibitors demonstrate promising efficacy against TNBC.•PARP1 and AR inhibitors are effective for TNBC under the guidance of gene subtyping.•Immunotherapy is the current development trend of targeted drugs against TNBC.</abstract><cop>Ireland</cop><pub>Elsevier B.V</pub><pmid>33069769</pmid><doi>10.1016/j.canlet.2020.10.016</doi><tpages>12</tpages><orcidid>https://orcid.org/0000-0001-5582-0020</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0304-3835 |
| ispartof | Cancer letters, 2021-01, Vol.497, p.100-111 |
| issn | 0304-3835 1872-7980 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2452100566 |
| source | MEDLINE; ScienceDirect Journals (5 years ago - present) |
| subjects | Androgens Animals Antineoplastic Agents - therapeutic use Antioxidants Biosynthesis Breast cancer Cancer therapies Cell cycle Chemotherapy Clinical trial Clinical trials Cytochrome Deoxyribonucleic acid DNA DNA damage DNA methylation DNA repair Drug development Drug Resistance, Neoplasm Drugs Enzymes Female Growth factors Humans Immunotherapy Kinases Medical prognosis Metabolism Metastases Molecular Targeted Therapy Proteins Quality of life Radiation therapy Targeted drug Therapeutic resistance TNBC Triple Negative Breast Neoplasms - drug therapy Triple Negative Breast Neoplasms - metabolism Triple Negative Breast Neoplasms - pathology Tumor microenvironment |
| title | Triple-negative breast cancer therapeutic resistance: Where is the Achilles' heel? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T18%3A26%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Triple-negative%20breast%20cancer%20therapeutic%20resistance:%20Where%20is%20the%20Achilles'%20heel?&rft.jtitle=Cancer%20letters&rft.au=Bai,%20Xupeng&rft.date=2021-01-28&rft.volume=497&rft.spage=100&rft.epage=111&rft.pages=100-111&rft.issn=0304-3835&rft.eissn=1872-7980&rft_id=info:doi/10.1016/j.canlet.2020.10.016&rft_dat=%3Cproquest_cross%3E2465722133%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2465722133&rft_id=info:pmid/33069769&rft_els_id=S0304383520305425&rfr_iscdi=true |